NasdaqGS:BDTXBiotechs
Can Black Diamond Therapeutics’ (BDTX) Silevertinib CNS Data Redefine Its Precision Oncology Strategy?
Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026.
The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types.
We’ll...